DOVONEX Cream 50 5 Milligram
Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Summary of Product characteristics
(SPC)
04-05-2024
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
CALCIPOTRIOL HYDRATE
Available from:
McDowell Pharmaceuticals
Dosage:
50 5 Milligram
Pharmaceutical form:
Cream
Authorization date:
2010-11-12
Summary of Product characteristics
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Dovonex 50 micrograms/g Cream
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each gram contains 50 micrograms of calcipotriol (as the hydrate).
Excipients: Contains cetostearyl alcohol
For a full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Cream
_Product imported from the UK_
Soft white cream.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Dovonex Cream is indicated for the topical treatment of plaque psoriasis (psoriasis vulgaris). Dovonex cream may also
be used in combination with topical corticosteroids.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
ADULTS
The cream should be applied to the affected area once to twice daily. Twice daily application of the cream is often
preferred initially. Application of the cream can be reduced to once daily when appropriate. Maximum weekly dose
should not exceed 100g.
Dovonex Cream in combination with corticosteroids (e.g. administration of Dovonex in the morning and steroid in the
evening) is effective and well tolerated.
CHILDREN
_Over 12 years_
Dovonex Cream should be applied to the affected area twice daily. Maximum weekly dose should not exceed 75g.
_Aged 6 to 12 years_
Dovonex Cream should be applied to the affected area twice daily. Maximum weekly dose should not exceed 50g.
_Under 6 years_
There is limited experience of the use of Dovonex Cream in this age group. A maximum safe dose has not been
established.
There is no experience of use of Dovonex in combination with other psoriasis therapies in children.
IRISH MEDICINES BOARD
________________________________________________________________________________________________________________________
_Date Printed 16/11/2010_
_CRN 2087161_
_page number: 1_
4.3 CONTRAINDICATIONS
Known hypersensitivity to any of the ingredients. Du
Read the complete document
